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ABSTRAK 
 
Virus denggi boleh berjangkit melalui pemindahan darah daripada penderma darah yang 
telah dijangkiti kepada penerima. Di Malaysia, peningkatan  kes jangkitan denggi boleh 
menyumbang kepada kewujudan penderma darah yang asimptomatik dan meningkatkan 
risiko pemindahan darah yang tercemar dengan virus ini. Oleh itu, objektif kajian ini 
adalah untuk mengkaji prevalen NS1 denggi antigen di kalangan penderma darah dan 
menentukan data demografi penderma darah di Pulau Pinang dan Perak. Seramai 374 
penderma darah secara sukarela telah direkrut daripada dua kempen derma darah yang 
dianjurkan oleh Hospital Pulau Pinang, Pulau Pinang dan Hospital Raja Permaisuri 
Bainun, Ipoh, Perak dari April hingga Mei 2016. Daripada setiap kempen, 187 penderma 
darah secara sukarela telah mendaftar dan ujian saringan NS1 denggi antigen telah 
dijalankan terhadap semua sampel. Hasil kajian mendapati kesemua 374 sampel adalah 
negatif untuk NS1denggi antigen. Umur purata penderma darah adalah 36 tahun. 
Penderma darah daripada kumpulan darah O Rh positif adalah paling ramai (42%, 157 
daripada jumlah penderma darah) dan diikuti oleh penderma darah daripada kumpulan 
darah B Rh positif (29.7%, 111 daripada jumlah penderma darah), A Rh positif (23.5%, 
88 daripada jumlah penderma darah) dan seterusnya AB Rh positif (4.8%, 18 daripada 
jumlah penderma darah). Majoriti penderma darah ialah lelaki (64.7%), berbanding 
dengan penderma darah perempuan (35.3%). Majoriti penderma darah terdiri daripada  
kaum Cina (338 penderma darah), diikuti oleh kaum Melayu (27 penderma darah) dan 
India (9 penderma darah). Kesimpulannya, NS1 denggi antigen denggi tidak dikesan di 
kalangan penderma darah di dua pusat pengumpulan darah di Pulau Pinang dan Perak. Ini 
xv 
 
menunjukkan bahawa tiada penderma darah yang menderma darah pada peringkat 
viraemia dan juga program saringan penderma yang sedia ada adalah efektif bagi 
memastikan jangkitan denggi menerusi pemindahan darah adalah minimum. Data 
demografi menunjukkan penderma darah dengan kumpulan darah yang paling biasa 
adalah O Rh positif, penderma lelaki lebih banyak daripada penderma wanita dan 
penderma darah kaum Cina adalah paling ramai. Data yang dikumpulkan dalam kajian ini 
mungkin berguna dalam memastikan aspek keselamatan dalam aktiviti transfusi serta 
dalam perancangan aktiviti derma darah, saringan penderma dan pengurusan inventori 
darah. 
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ABSTRACT 
 
Dengue virus is one of the emerging agents that can be transmitted via blood transfusion 
from infected blood donors to recipients. In Malaysia, the increase in dengue infection 
may contribute to the existence of asymptomatic blood donors and increase the risk of 
blood transfusions contaminated with this virus. Thus, the objectives of this study were to 
investigate the prevalence of NS1 dengue antigen among blood donors and ascertain the 
demographic data of blood donors in Penang and Perak. A total of 374 voluntary blood 
donors were recruited from two blood donation campaigns organised by Hospital Pulau 
Pinang, Penang and Hospital Raja Permaisuri Bainun, Ipoh, Perak from April to May 
2016. From each centre, 187 voluntary blood donors were enrolled, blood was collected 
and Dengue NS1 Ag was screened on all the samples. The study showed, all 374 samples 
were found to be negative for the Dengue NS1 antigen. The mean age for blood donors 
was 36 years. Blood group O Rh positive blood group was the commonest (42%, 157 of 
the total blood donors) followed by B Rh positive blood group (29.7 %, 111 of the total 
blood donors), A Rh positive (23.5%, 88 of the total blood donors) and AB Rh positive 
(4.8%, 18 of the total blood donors). There were more male blood donors (64.7%) 
compared to female blood donors (35.3%). Majority of these blood donors were Chinese 
(338 blood donors), followed by Malays (27 blood donors) and Indians (9 blood donors). 
In conclusion, there is no NS1 dengue antigen detected among blood donors in two blood 
collection centres in Penang and Perak. This indicates that none of the blood donor at the 
time of donation was in viraemic stage which translates that the established donor 
screening program is effective to ensure that dengue transmission through transfusion is 
xvii 
 
minimal. Demographic data of these blood donors showed that the most common blood 
group was O Rh positive, men donated more than women and Chinese blood donors were 
the commonest. Data collected in this study may be useful to ascertain the safety aspects 
of clinical transfusion and in the planning of blood donation activities, donor recruitment 
and blood inventory management. 
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
            1.1 Epidemiology of Dengue Virus 
 
1.1.1 Global Health Problem 
 
 
Dengue is a vector-borne disease that leads to health problems worldwide. Overall, 100 
million dengue cases is estimated per year, with roughly 500 000 severe dengue patients 
requiring continuous treatment in hospital (Back et al, 2013). Dengue infection has been 
prevalent in more than 100 countries including Africa, the Americas, the eastern 
Mediterranean, Southeast Asia and the Western Pacific. In 2011, there is an increase in 
dengue cases documented in the United States and Brazil, with 1.1 million cases and 764 
305 cases of severe dengue (Felix et al, 2012). 
 
A widespread outbreak of dengue infection was recorded in Comoros, after time-to-time 
cases in the mild locales of North Africa and the Mediterranean in the 1990s. However, 
dengue has been common in tropical Africa, in spite of the fact that dengue hemorrhagic 
fever (DHF) is uncommon. Europe and Antarctica never come across with any dengue 
cases, but by the time, dengue infection has spread across boundaries. In Asia, DHF 
spread dramatically from the first epidemic country, Philippines, followed by 
Thailand, Malaysia, Singapore and Vietnam (D. Teo et al, 2009). 
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In Florida and Hawaii, the presence of the vector is the main cause of the epidemiology 
of dengue. All classified serotypes of dengue virus found in the prevalent areas in 
Puerto Rico, the Virgin Islands and American Samoa. In United State, most tourists who 
were back from the Caribbean, Latin America and Asia also experienced a sudden onset 
of fever caused by dengue (Vazquez J et al, 2013). 
 
Dengue infection occurs in most periods in Queensland, although the virus is not 
commonly found in Australia. Virus transmission from infected humans to local 
population by primary vector causing epidemic of the disease. In the past 16 years, 3550 
cases of infection have been reported, with approximately 200 cases a year in Australia. 
An average of 200 cases identified without clinical manifestations with 5 deaths due to 
dengue within this interval (Hilary J. Bambrick et al, 2009). 
 
 
Treatment and deaths caused by dengue among children in Asia has exceeded malaria in 
the mid-70s (Gubler, 2002). In the most recent couple of years, climate changes have led 
to the extension of mosquito breeding sites. Gradual increase of people, the social 
process whereby cities grow and societies become urban, insufficient water 
administration, ineffective vector management and globalization, contribute to expand 
mosquito habitat. A rapid spread of dengue, very likely could extend and alter antigenic 
properties of the virus, including new serotypes and genetic make-up with a larger 
outbreaks possibility (D. Teo et al, 2009). Moreover, dengue transmitted rapidly, in the 
suburban and rural areas (Gubler, 2002). 
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1.1.2 Dengue In Malaysia 
 
After an epidemic of dengue infections in 1973, many dengue cases are reported in 
Malaysia. In the early 1990s, approximately 5000 cases were documented each year. A 
dramatically increase pattern of dengue cases were reported in 1999 to 2007, with 44.3 
cases to 181 cases per 100,000 population (Nizal et al, 2012). Unpublished ongoing 
systematic collection and data analysis, from the Ministry of Health Malaysia, showed an 
increase of 29,803 dengue cases in 2010 compared with the past 9 years (Cheah et al, 
2014). The rate of dengue infection has increased continuously, within rapidly 
developing and population growth area (Nizal et al, 2012). 
 
 
 
 
 
 
 
                                                               
                                                   Figure 1: Dengue cases In Malaysia  
 An increase of dengue cases was recorded in Malaysia from 2013 to 2015. An increase 
of 65 352 cases were reported from 2013 to 2014, while from 2014 to 2015, an increase 
of 12 138 cases documented (Ministry of Health, 2015). 
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Continuous increase in dengue cases were documented in the country, since November 
2015 until the first week of 2016. The number of cases increased by 826 cases (33%), 
with 2511 cases in the last week of 2015 to 3337 cases of dengue early 2016. In the past 
two years, dengue cases increased dramatically, but the number of cases reported for the 
first week of 2016 (3337 cases) was higher than the number of cases reported for the 
same period in 2015 (2633 cases). Overall, there was 12,138 cases (11.2%) were reported 
in 2015 compared to 108,698 cases in 2014 (Ministry of Health Malaysia, 2016). 
 
Dengue cases were reported increased in all 13 states of Malaysia. In the first week of 
2016, 4 deaths were accounted from Kuala Lumpur, Selangor, Putrajaya, Negeri 
Sembilan and Terengganu. The number of affected areas increased to 1,044 in the early 
weeks of 2016 compared to 907, the previous week. Specifically, seven states, namely 
Selangor (122), Johor (22), Perak (8), Pulau Pinang (4), Sabah (2), Negeri Sembilan (2) 
and Wilayah Persekutuan Kuala Lumpur (WPKL) & Putrajaya (1) showed an increase in 
hotspots area, with an expansion from 145 to 161 localities (Ministry of Health Malaysia, 
2016).  
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Provincial studies around Malaysia demonstrated that the measure of raindrop, 
temperature, and moistness were all straightforwardly connected to epidemic of dengue 
infection. A reported case of dengue infection is highest in the first quarter of the year 
and between June and November. Even so, monthly systematic observation shows 
dengue infection can occur throughout the year. A few geological observation and a 
schematic description  have exhibited, that the expanding urbanization in Malaysia was a 
main factor for the frequency of dengue infection  nationwide (Zaki et al 2014). 
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1.2 Dengue Virus 
 
1.2.1 Genome and Structural Features 
 
 
 
 
 
 
 
 
 
  
Figure 2: Dengue Virus Genome (Adapted from: Perera et al, 2008) 
Dengue virus consists of single stranded RNA genomes and surrounded by an envelope. 
The genome corresponds to a range of nucleotides, which encode 3411 amino acids. The 
entire genome contains seven proteins, with three structural proteins, membrane protein, 
core  and envelope protein, besides seven nonstructural proteins, including NS1, NS2a, 
NS2b, NS3, NS4a, NS4b and NS5 (Castro-Jorge LA et al. 2010). The viral structural 
proteins are part of a complete virus structure and not directly involved in viral 
replication. The nonstructural proteins present in cells infected with virus and not at the 
detectable level in a complete virus structure (Back et al, 2013). 
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The nonstructural protein 1 (NS1) consist of glycoprotein with two glycosylation sites. 
NS1 is produced in the endoplasmic reticulum and then processed in the Golgi apparatus 
(Winkler G. et al. 1989). The presence of NS1 protein in the process of viral replication is 
not known, but it gives the impression in terms of virus infection and the development 
of a disease or morbid condition (Libraty et al. 2002). NS1 protein also produced by cells 
infected by the virus, known as NS1 secreted from infected cells (sNS1). sNS1 plays a 
role in structure and function of the immune system to produce antibodies. Production of 
antibodies induces changes in endothelial cell function caused by the reaction between 
the host protein and endothelial cells (Back et al, 2013). 
 
 
 
 
 
 
 
 
                     
Figure 3: Maturation of dengue virus (Adapted from: Perera et al, 2008) 
Dengue virus can be in the form of infectious or non-infectious in the body. Immature 
and mature virus is different from the structure of the membrane and envelope. Changes 
in the structure of the immature to mature occurred when the virus travel through the 
Golgi apparatus 
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1.2.2 Circulating Serotypes 
 
Dengue virus is divided into four serotypes, namely, DENV 1-4 with differences in 
structure and function in the immune system. The four serotypes of dengue rise from 
forest in Southeast Asia (Wang et al. 2000). Infection of a specific serotypes only provide 
immunity against that serotypes only, without giving immunity to infection by other 
serotypes. In general, all serotypes are associated with dengue outbreaks. Recent studies 
have shown, genotype diversity between the four serotypes contribute to disparity in 
dengue outbreaks (D. Teo et al, 2009). 
 
In Malaysia, a high and persistent incident of dengue cases is documented in the presence 
of infection by all serotypes. Even so, some serotypes of dengue infection became 
dominant for a long period. Dengue infection caused by DENV 3 is high between the 
years 1992-1995 and 2001-2002 (Ravindran et al. 2001). DENV 2 caused the dengue 
epidemic between years 1998-2000, while DENV 1 contributed to an increase of dengue 
cases between 2004-2006. In the past 2 years, until 1969, dengue serotypes 4 become 
dominant. After that, dengue cases caused by DENV 4 decreased throughout of the year, 
until an increase in 2001. The Institute for Medical Research (IMR), Malaysia, reported 
that, DENV 3 contributed to dengue cases between 2008 and 2009 (Cheah et al 2014). 
According to a research conducted in India, within all four serotypes, DENV 2 and 
DENV 3 contributed to the increase in cases of severe dengue and dengue hemorrhagic 
fever infection among Asians (Nizal et al, 2012) 
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1.2.3 Life Cycle of Dengue Virus 
 
 
 
 
 
 
 
 
 
 
 
           
        Figure 4: Life Cycle of Dengue Virus (Adapted from: Screaton et al. 2015) 
The virus envelope protein binds to receptors molecules and trigger cellular process 
called receptor-mediated   endocytosis. Then, the virus   internalized   into a structure 
called endosomes. The viral responds to lower pH in the endosomes, and form spike like 
structure. The spike allows penetration of endosome membrane and release capsid to 
cytoplasm. The capsid breaks apart and releases viral RNA. Viral RNA travel to rough 
endoplasmic reticulum. The whole viral genome is translated to a single long polyprotein 
chain. The capsid protein is in the cytoplasmic site on the endoplasmic reticulum. The 
envelope and premembrane  protein are in the lumen site and activated by host peptidase 
enzyme (Back et al, 2013). 
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In cytoplasm, viral protein activates other protein in polyprotein chain. This protein 
aggregates to form RNA replication complex. Viral RNA attaches to replication complex 
to start synthesis positive sense strand of virus and translated to make viral protein. Viral 
RNA binds to capsid protein and packed into new immature virus particle. The virus 
travels through Golgi apparatus and continue to cell surface. Before reaching cell surface, 
premembrane protein is processed and virus becomes mature. New dengue virus released 
from cells (Back et al, 2013). 
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1.3 Dengue Transmission 
 
1.3.1 Vector 
 
 
 
 
Figure 5: Aedes aegypti  (Adapted from : WHO 2009) 
Aedes  aegypti  is  the  primary  vector  for  dengue virus. In spite of that, there is a 
possibility of infections caused by Aedes albopicturs and Aedes polynesiensis.  
 
Humans infected with dengue virus will be the host for virus replication. Female 
mosquitoes captured dengue virus by biting human with the presence of virus particles in 
the bloodstream. Female mosquitoes spread dengue virus during each consumption (D. 
Teo et al, 2009). Environment with stagnant water facilitates female mosquitoes to lay 
eggs. This indirectly contributes to the increase in the number of mosquitoes during the 
rainy season and an increase in dengue cases (Back et al, 2013). Dissemination of dengue 
virus in some areas, indirectly gives an overview of the vector distribution (WHO 1997). 
The incubation period and virus replication in the vector depends on the temperature of 
the external environment and the type of virus involved (D. Teo et al, 2009).  
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1.3.2 Transplant 
 
Dengue infections through transplants have been documented in Singapore. The recipient 
received a renal transplant from a living donor. The recipient developed an immune 
response following the transplant procedure, with an abnormal decrease in the number of 
platelets (Tan et al. 2005). Transmission of dengue through bone marrow transplants was 
reported during the dengue outbreak in Puerto Rico. The donor showed symptoms of 
dengue infection such as fever and headache while the recipient had fever, four days after 
the transplant and died (Rigau-Pereze et al.,2001). 
 
In German, dengue transmission was reported through peripheral blood stem cell 
transplant. The recipient experienced abdominal pain, with oxygen deficiency and high 
acidity. Dengue screening performed on the recipient’s blood, after three days of the 
transplant procedure. The result was negative for dengue antibodies but positive for 
dengue antigen and dengue RNA. The recipient had circulatory arrest and died nine days 
after transplant. Further investigation revealed that the donor had just returned from Sri 
Lanka, a place with a high prevalence of dengue fever and other infectious diseases 
(Punzel et al.  2014). 
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1.3.3 Nosocomial 
 
Community acquired dengue transmission via the skin mucosa membrane and needle 
stick injury were also recorded. Transmission via mucocutaneous occurs when the blood 
of patients infected with dengue virus splashed onto face of a health personnel. The 
health worker showed signs and symptoms of dengue virus infection. Further screening, 
found that patients and health care workers infected with dengue virus serotypes 3 (Chen 
& Wilson, 2005) 
 
In Hungary, there are cases of dengue infection through needle stick injury that occurred 
in the hospital, where a patient was infected with dengue after a mosquito bite while on 
holiday in Bangkok. The medical officer who took the blood of the infected patient, 
accidently punctured her finger. A week later, she showed a vague feeling of discomfort 
or unease, fever, visible lesions on the skin and muscular rheumatism (Nemes et al 2004). 
There are also a few articles published related to dengue infection through needlestick 
injury. Community acquired dengue transmission in endemic areas through needlestick 
injury is still in obscurity. Therefore, laboratory personnel and front line need to take 
precaution when dealing with patients (Chen & Wilson, 2005) 
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1.3.4 Vertical  Transmission 
 
There are documented cases of dengue infection involving transmission from mother to 
baby.  Infected baby had fever a day after birth. There were also cases where 
transmission of dengue virus occured from a pregnant woman, found to suffer from 
dengue hemorrhagic fever before delivery (D. Teo et al, 2009). 
 
In Sri Lanka, a number of cases related to dengue infection through vertical transmission 
had been reported, despite most cases overlooked it as complications during pregnancy 
and not well diagnosed. There were cases where the newborn showed symptoms of 
dengue. Dengue screening test results was strongly positive for dengue antigen and 
weakly positive for dengue Ig M.  The mother presented with fever during delivery and 
dengue screening tests were positive for both dengue antibodies (Sinhabahu et al. 2014). 
 
Another case was reported in Sri Lanka, where the newborn had a fever a few hours after 
birth. The mother showed an abnormal decrease in the number of platelets. Dengue 
antibody tests carried out on blood samples from newborn and the mother. Both were 
positive for dengue Ig M and Ig G. Vertical transmission of dengue is quite difficult to 
identify unless the mother or newborn shows symptoms of infection. Most positive cases 
of dengue, through vertical transmission was diagnosed, when the mother has fever 
during labor (Lokuarachchi & Jayasekaran, 2007). 
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1.3.5 Transfusion Associated 
 
 
Dengue infection can lead a person to have a high viral load up to 109 copies/ml. Patients 
with dengue hemorrhagic fever will have a higher viral load than patients with dengue 
fever. Approximately 50-80% of reported cases of infection are asymptomatic. Therefore, 
there is a possibility of dengue infection through transfusion from asymptomatic donors 
to recipients (Mohammed et al 2008). 
 
 
In Mawan, Hong Kong, dengue infection through blood transfusion was reported in areas 
of low prevalence of dengue. The blood donor showed symptoms of dengue fever, a day 
after donating blood. Dengue screening was performed using blood samples from 
donated blood, by using reverse-transcriptase PCR. The presence of dengue antigens 
identified through screening tests that had been carried out. During epidemics of dengue 
in Puerto Rico, Brazil, dengue screening was performed on donated bloods (Stramer et al, 
2009). Results through nucleic acid testing, found 12 donors out of 16521 donors were 
positive for dengue (Mohammed et al 2008).  
 
 
Dengue infection through blood transfusion has also been reported in Singapore. Donors 
had a fever after giving blood. Screening of dengue found that donor was infected with 
dengue serotype 2. Both recipients of packed cells and plasma products (fresh frozen 
plasma), developed fever after transfusion. Screening tests that had been carried out to 
the recipient, using PCR, gave positive results for dengue antigen (Tambyah et al, 2008). 
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A dengue screening conducted among 329 volunteer donors in an area with a high 
number of dengue cases in Thailand. Dengue screening was found on 29 donors positive 
to dengue Ig M, while 2 donors were positive for dengue RNA (Poblap et al, 2006).  In 
Indonesia, a study of dengue was carried out on 785 volunteer blood donors. Of these, 8 
dengue infected asymptomatic donors have been identified (Beckett et al, 2005). Dengue 
screening was also carried out in areas with a high prevalence of dengue in Colombia. 
Out of 3189 blood donors, 215 donors were asymptomatic dengue virus infection 
(Mendez et al, 2006). 
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Table 1: Dengue and Donor Deferral (Adapted from: D. Teo et al, 2009)  
 
 
 
 
 
 
 
                 
 
 
 
 
 
*Endemic for dengue. †Non-endemic except parts of Northern Australia. ‡Non-endemic. 
 
Generally, history of infections, health condition and travelling history of blood donors 
are points to consider when differing blood donor.  In Malaysia blood donors infected 
with the dengue virus will be deferred for a period of 6 months after full recovery 
(National Blood Centre, 2014). 
 
 
Country Donor deferral measures for dengue 
Singapore* 6 months deferral for history of 
dengue infection 3 weeks deferral 
for history of fever No travel-
related deferral for dengue 
Hong Kong* 6 months deferral for history of 
dengue infection 2 weeks deferral 
for history of fever No travel-
related deferral for dengue  
Sri Lanka* No specific deferral for history of 
dengue infection 2 weeks deferral 
for history of fever No travel-
related deferral for dengue 
Australia† 4 weeks deferral for history of 
dengue infection No travel-related 
deferral for dengue 
New Zealand‡ 4 weeks deferral for history of 
dengue infection No travel-related 
deferral for dengue  
UK‡ 2 weeks deferral for history of 
dengue infection No travel-related 
deferral for dengue 
United States‡ 4 weeks deferral for history of 
dengue infection No travel-related 
deferral for dengue 
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1.4 Dengue Infection 
 
 
1.4.1 Pathogenesis 
 
Early signs and symptoms of dengue infection present between 4 to 7 days after 
infection. A person infected with dengue may be asymptomatic or show signs of chronic 
infection. Symptoms of dengue infection, characterized by clinical manifestation are 
variable according to severity of the infection. Symptoms of infection may fluctuate in a 
short period especially patients with plasma leakage. Dengue virus can be detected day 
before the appearance of signs and symptoms of infection. Virus detectable in the blood 
stream until the fifth day of infection for primary infection and until day four for 
secondary infection (Ministry Of Health, 2015).  
 
The possibility of dengue hemorrhagic fever cases is high with persistent occurrence of 
multiple serotypes of dengue. The presence of dengue antibody can be detected in the 
bloodstream before infection, namely through the transmission of maternal antibodies or 
the effects of previous dengue infection. Dengue infection can be more severe, with the 
presence of dengue antibody before infection, namely through the transmission of 
maternal antibodies or the effects of previous dengue infection. In a study, involving 
medical examination of a deceased, dengue antigen found in phagocytic cells of the 
reticuloendothelial system, lymph and connective tissue (Cheah et al, 2014). 
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1.4.2 Symptoms and Clinical Manifestations 
 
Indications and signs of dengue infection vary from asymptomatic infections to dengue 
fever without having any distinguishing features, infections in critical phases and 
complications that capable of causing death (Ministry of Health, 2010). Symptoms of 
dengue fever include abnormal high body temperature, headache, muscular rheumatism, 
neuralgic pain, nausea and lesions on the skin. There are also patients with dengue 
hemorrhagic fever indicates presence of blood in the urine, nosebleed and abnormally 
dark tarry stools containing blood (Nizal et al, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Dengue case classification and levels of severity 
                                              (Adapted from: WHO Dengue Guidelines for Diagnosis,          
                                              Treatment, Prevention and Control, 2009) 
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1.4.3 Treatment 
 
 
Nowadays, treatment of dengue patients focused more on the management of body fluids. 
Even so, patients should closely monitored during treatment to prevent excessive fluid 
(Cheah et al, 2014). Until now, the treatment is more to treat symptoms of dengue 
infection because there are no specific medicines to treat dengue. Complications of 
dengue infection at the critical level can be reduced if intravascular fluid leakage detected 
early and treated promptly (D. Teo et al, 2009). A sufficient and comprehensive 
treatment can reduce mortality up to 1% compared with untreated patients (WHO, 1997). 
 
Development of sophisticated treatment for dengue focuses on the different stages of 
viral replication and interaction between the envelope and membrane proteins. There are 
studies done to prevent the production of new copies of the virus, by inhibiting the 
formation of structure through mechanism or interaction of membrane and envelope 
proteins (Back et al, 2013). 
 
Blood transfusion in dengue patients should only be considered, if the patient shows signs 
of bleeding. Justification for platelet count as an indication of platelet transfusions for 
dengue patients were still in obscurity. Nevertheless, most clinical guidelines have been 
set platelet transfusion should be performed when patients experience severe bleeding 
and if the platelet level drops accompanied by bleeding (D. Teo et al, 2009). 
 
 
